BILL ANALYSIS

HR10787

BULLISH

To amend title XVIII of the Social Security Act to exclude urological and ostomy supplies from competitive acquisition programs under the Medicare program for 5 years, and for other purposes.

HR10787 (To amend title XVIII of the Social Security Act to exclude urological and ostomy supplies from competitive acquisition programs under the Medicare program for 5 years, and for other purposes.) has been assessed with a bullish outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bullish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR 10787 protects Medicare pricing for urological and ostomy supplies, directly benefiting manufacturers like $BDX and distributors like $OWI.

The bill is in early stages (referred to committee) and faces a long legislative path, but its protectionist mechanism is clear.

No direct federal funding is involved; the impact is preventing future Medicare cost-containment measures on these specific products.

How HR10787 Affects the Market

The bill is a niche positive for the medical supplies sector, specifically companies with exposure to Medicare Part B urological and ostomy supplies. $BDX is the primary beneficiary given its market position in catheters. and $SNN have secondary exposure. The impact is purely defensive—protecting existing margins rather than creating new revenue streams. The early legislative stage means this is a monitoring event, not an immediate catalyst.

Bill Details

Metric	Value
Bill Number	HR10787
Market Sentiment	bullish
Event Date	October 9, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR 10787 proposes a 5-year exemption for urological and ostomy supplies from Medicare's Competitive Acquisition Program. This is a direct positive signal for manufacturers and distributors of these specific chronic-care products, protecting their Medicare pricing from competitive bidding pressures. The bill is in early legislative stages, but the protectionist intent for this niche is clear.

Full AI Market Analysis

Rep. Murphy (R-NC) introduced HR 10787 on October 9, 2026, which was subsequently referred to the House Committees on Energy and Commerce and Ways and Means. The bill is in an early legislative stage. The core mechanism is an amendment to the Social Security Act to exclude urological and ostomy supplies from Medicare's Competitive Acquisition Program (CAP) for five years. There is no authorized spending; the bill is a regulatory exemption that prevents CMS from using competitive bidding to lower reimbursement rates for these specific supplies. No convergence signals were provided in the candidate context, so this analysis stands alone as a niche protectionist maneuver within Medicare policy. The structural winners are companies with direct exposure to Medicare Part B urological and ostomy reimbursement. $BDX (Becton Dickinson) is the primary beneficiary given its market-leading position in urological catheters and drainage systems. $SNN (Smith & Nephew) benefits through its Advanced Wound Management and Ostomy Care segments. (Owens & Minor) benefits as a distributor of these medical supplies. The legislative path is long: the bill must pass through two committees, receive a House floor vote, find a Senate companion, and be signed into law. The early stage and narrow scope make this a monitoring event rather than an immediate catalyst.